• Home
  • Study Details
Coming Soon

P-RAD(+)TN - DCT

You are being asked to take part in this study because you have triple negative (TN) breast cancer that has spread to your lymph nodes. You are also planning to get chemo-immunotherapy treatment before surgery. Radiation therapy (RT) has been shown to improve the body's immune response against tumors when it is given with a drug called pembrolizumab. The purpose of this study is to find the best and safest dose of radiation (low or high) when given with pembrolizumab. Radiation is measured in Gy (pronounced "gray"). You will be randomly assigned (like flipping a coin) to receive either a low dose RT boost (9 Gy) or a high dose RT boost (24 Gy). The RT will be given with one dose of pembrolizumab. This is a hybrid decentralized study where some if not all assessments may be performed close to your home.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study will start enrolling soon.

United States (Nationwide)

Additional Study Information

Principal Investigator

Dana Casey
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Breast)

IRB Number

25-2165

Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research